Want to see MREO full AI Analyst Report?
MREO Stock Chart & Stats
$0.27
>-$0.01(-1.10%)
At close: 4:00 PM EDT
$0.27
>-$0.01(-1.10%)
Day’s Range― - ―
52-Week Range$0.20 - $2.37
Previous CloseN/A
Volume389.50K
Average Volume (3M)6.94M
Market Cap
$45.49M
Enterprise Value$21.97
Total Cash (Recent Filing)$30.12M
Total Debt (Recent Filing)$1.03M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 17, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding159,690,980
10 Day Avg. Volume1,533,534
30 Day Avg. Volume6,942,574
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside1011.11% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$1.77M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal reported debt reduces solvency pressure and interest-related demands compared with a highly leveraged biotech. This gives Mereo greater flexibility to allocate capital toward clinical programs and partnerships, although its declining asset base and continuing losses still constrain overall financial resilience.
Capital-light Partnership StrategyThe Sentynl agreement supports a capital-light development model by creating potential upfront, research, milestone, and royalty economics without requiring Mereo to commercialize the therapy alone. It also gives the company an external partner to support manufacturing and future U.S. commercialization.
Rare-disease Pipeline OpportunityAlvelestat addresses a defined rare-disease population with substantial unmet medical need and is described as a potential first-in-class oral therapy. Advancing toward a Phase 3 program could create a meaningful value inflection and strengthen Mereo’s partnering and commercialization prospects.
Bears Say
Near-zero Revenue And Persistent LossesThe current business has little top-line support and remains materially unprofitable after a sharp deterioration from positive profitability in 2021. Persistent losses reduce internal funding capacity, increase reliance on partnerships or financing, and make future earnings power highly dependent on clinical and commercial execution.
Continued Cash BurnMaterially negative operating and free cash flow shows that Mereo is not yet self-funding its development activities. Continued cash consumption creates recurring financing needs and can limit the pace or breadth of clinical investment, even though reported burn improved from earlier periods.
Nasdaq Compliance And Listing RiskThe extended bid-price deficiency remains a business and financing overhang rather than a temporary trading issue. Failure to regain compliance could lead to delisting, reducing market visibility and potentially complicating access to investors and capital needed to fund ongoing clinical programs.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $0.20 and its highest was $2.37 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $45.49M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 17, 2026 which is in 61 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Aug 11, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.002.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.02.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,690,980 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went up 12.132%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (1011.11% Upside)
$3.00 (1011.11% Upside)
Hedge Fund Trend
Decreased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MREO Stock 12 Month Forecast
Average Price Target
$3.00
▲(1011.11% Upside)
Technical Analysis
Ownership Overview
0.81%
Insiders
0.09% Mutual Funds
26.80% Other Institutional Investors
72.21% Public Companies and
Individual Investors